Neuroscience

#Drug discovery #Events #Neuroscience #Webinar

Webinar: The opportunities in neuroscience drug discovery

Hosted by Drug Discovery World and sponsored by Emulate, this free webinar explores where innovation is taking place within neuroscience drug discovery.  The webinar sees experts and leaders from the neuroscience sector discuss where innovation is occurring and what the challenges are to overcome for drug… Read More

Webinar date:
Sponsored by Emulate
#News

Human neuron
#Amyotrophic lateral sclerosis (ALS) #Early access #FDA #Neuroscience #Spinogenix

FDA okays access programme for ALS synaptic regenerative therapy

The Food and Drug Administration (FDA) has authorised Spinogenix to begin its Expanded Access Program (EAP) for SPG302 in the United States for people with amyotrophic lateral sclerosis (ALS) that meet programme eligibility criteria.  SPG302 is being developed as the first synaptic regenerative approach to treating ALS, with the potential… Read More

#News #Regulatory #Trending News

#Alchemab Therapeutics #Amyotrophic lateral sclerosis (ALS) #Dementia #Eli Lilly #Neuroscience

ALS drug licensing agreement confirmed

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions. The transaction is worth up to a total of $415 million, including an undisclosed upfront payment, potential discovery, development, and commercialisation… Read More

#Business & Investment #News

#Drug discovery #Events #Neuroscience #Webinar

Webinar: Where is the innovation in neuroscience drug discovery?

Hosted by Drug Discovery World and sponsored by Emulate, this free webinar explores where innovation is taking place within neuroscience drug discovery.  The webinar sees experts and leaders from the neuroscience sector discuss where innovation is occurring and what the challenges are to overcome for drug… Read More

Webinar date:
Sponsored by Emulate
#News

Parkinson's disease
#Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Research reveals “compelling” new drug target for Parkinson’s

Researchers have identified a key enzyme driving forms of Parkinson’s, offering a promising new drug target for the condition.  In Parkinson’s, a protein known as alpha-synuclein builds up in clumps called Lewy bodies in nerve cells in the brain. These clumps of protein stop these cells from… Read More

#Editor's Choice #News

Gold compound
#Alzheimer's #BioInnovation Institute #Biotech hubs #Cognition Therapeutics #India #Interview #Market reporting #Neurodegenerative disorders #Neuroscience #Pregnancy #Start-ups #Women's health

Podcast: Where are scientists making waves in drug discovery?

This is the latest episode of the free DDW narrated podcast, titled “Where are scientists making waves in drug discovery?”, which covers three articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “How pharma is targeting advances in Alzheimer’s treatments”, “The start-up disrupting… Read More

#News

Lecanemab
#Alzheimer's #Biogen #Eisai #European Commission #Monoclonal antibodies #Neuroscience

Lecanemab gets EU approval in early Alzheimer’s

The European Commission (EC) has granted Leqembi (lecanemab) Marketing Authorisation (MA) in the European Union (EU).  The approval makes the medicine the first therapy that targets an underlying cause of Alzheimer’s disease (AD) to be granted a MA in the EU.  Lecanemab is indicated for the treatment of adult patients… Read More

#News #Regulatory #Trending News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Dementia #Therapeutic Antibodies #UK Dementia Research Institute

Scientists discover why Alzheimer’s drugs are effective

Scientists in the UK and Belgium have discovered new insights into how four different anti-amyloid drugs interact with amyloid beta protein, revealing why the drugs have had varying levels of success at treating Alzheimer’s disease. Amyloid beta is one of the toxic proteins which builds up in clumps… Read More

#News #Trending News

Patient holding pill in hand
#Alzheimer's #Neuroscience #Phase III trial #Tau protein #TauRx Pharmaceutics

Oral treatment could slow progress of Alzheimer’s disease

Researchers have reported a potential oral treatment for Alzheimer’s disease (AD) that slowed its progression over a period of at least 18 months.  Developed by Singaporean company TauRx Pharmaceutics, the scientists based in Aberdeen, UK, report that hydromethylthionine mesylate (HMTM) could be the first oral treatment for… Read More

#News

Mental health concept
#Antidepressants #Gut-brain interaction #Mental health #Neuroscience

A promising new target for mental health

DDW Editor Reece Armstrong speaks to Kara Margolis, MD, Director of the NYU Pain Research Center and Associate Professor at NYU College of Dentistry and NYU Grossman School of Medicine, and Mark Ansorge, Associate Professor of clinical neurobiology at Columbia University about recent research highlighting the importance between the gut… Read More

#Exclusive Content

Alpha-synuclein protein aggregate
#AC Immune #Immunotherapy #Neuroscience #Parkinson's #Phase II trial

Immunotherapy for Parkinson’s induces positive responses

AC Immune has announced additional interim safety and positive immunogenicity data from the Phase II VacSYn clinical trial evaluating ACI-7104.056, its anti-alpha-synuclein (a-syn) active immunotherapy candidate for early Parkinson’s disease (PD).  Dr Andrea Pfeifer, CEO of AC Immune, commented: “We continue to be encouraged by the data… Read More

#News

#Alzheimer's #Antibody drug conjugate (ADC) #hepatitis #Monoclonal antibodies #Oncology #Therapeutic Antibodies

This week in drug discovery (31 March – 4 April) 

News round-up for 31 March – 4 April by DDW Senior Digital Content Editor Diana Spencer. The headlines this week have demonstrated the importance of antibody therapies, particularly in treating cancer, but also as potential therapeutics for a range of other diseases including hepatitis D and Alzheimer’s. Read More

#News

Neurons in a brain with Alzheimer's disease
#Alzheimer's #Antibody #Gene therapy #Neuroscience #Tau protein #Voyager Therapeutics

Anti-tau antibody and gene therapy show potential in Alzheimer’s

A single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in preclinical studies.  Voyager Therapeutics will share the new data from its two preclinical programmes for Alzheimer’s disease (AD) at the 2025 International… Read More

#News

Therapeutic antibodies
#Alzheimer's #Antibodies #Cancer #Covid-19 #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies #Rare disease #Therapeutic Antibodies

Podcast: Where is the innovation in the therapeutic antibody market?

This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More

#News

#ALS #Arbor Biotechnologies #CNS #Financing #Gene therapy

Gene editing company announces $73.9m Series C financing

Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS).   The proceeds will support clinical development of the company’s lead therapeutic candidate, ABO-101, in primary… Read More

#Business & Investment #News

Hormones in the brain concept
#European Commission #Lundbeck #Neuroscience #Otsuka #Schizophrenia

Brexpiprazole’s EU approval extended to include adolescents

The European Commission (EC) has approved Otsuka’s Rxulti (brexpiprazole) for the treatment of schizophrenia in adolescents aged 13 years and older.  The drug was previously approved in the European Union in 2018 for the treatment of schizophrenia in adults.  The EC based its approval on a six-week trial of 316… Read More

#News #Regulatory